Pioneering the biotech industry back in the 70’s, Silicon Valley based Genentech is one of the world’s most innovative pharmaceutical companies and a leader in breakthrough lifesaving drugs, treatments, and technologies. Now part of Roche the combined entities have tens of thousands of patents and employ over 100,000 people in 100 countries who delivered over $68 B in revenue last year. Their transformational discoveries include the first targeted antibody for cancer, and the first medicine for primary progressive multiple sclerosis. Early 2022 saw Genentech get FDA approval in ophthalmology, with a bispecific antibody for two leading causes of vision loss; underscoring their commitment to people living with retinal conditions - age related macular degeneration (AMD), and diabetic macular edema (DME). In a world consumed by the pandemic over the past few years and the long-term ramifications ahead, a conversation with Genentech’s CEO, Alexander Hardy, on the Reboot Chronicles show was imperative, to say the least.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related